PhII failure in rare neurodegenerative disease? No matter, Biogen will motor on in Alzheimer's
Biogen’s fierce focus on disorders of the brain has hit another roadblock.
On Friday, the US drugmaker — which recently resurrected its amyloid-targeting Alzheimer’s drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
